Phase 1a/b Study on Safety of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers

NCT ID: NCT03270800

Last Updated: 2019-02-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-01-30
• Study Completion Date: 2018-12-23

Brief Summary

A Phase 1, multi-center, randomised, double-blind and adjuvant-controlled study to evaluate the safety, tolerability, and efficacy of IMX101 in H. pylori-negative and H. pylori-infected healthy volunteers.

The study will be conducted in 2 phases. Phase A: Study design contains 6 cohorts, each containing 8 subjects. Three cohorts (24 subjects) will be H. pylori-negative and 3 cohorts will be H. pylori-infected. Subjects fulfilling the inclusion criteria will be assigned to one of 3 sequential dose cohorts with a 3:1 randomisation to IMX101 or to CTA within each cohort.

Phase B: Two cohorts with H. pylori-infected subjects can be expanded up to 20 subjects in each cohort. The decision whether to expand the cohorts will be taken by the Sponsor and the DSMB, as soon as the results of the safety and efficacy analyses are available.

Up to 72 subjects collectively in Phases A & B will be recruited. depending on immunogenicity status.

Conditions

Helicobacter Pylori Infected Subjects; Helicobacter Pylori Naive Subjects

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

IMX101 vaccine as intradermal and sublingual application

IMX101 vaccine will be administered intradermally and sublingually

Group Type: EXPERIMENTAL

IMX101 vaccine

Intervention Type: BIOLOGICAL

Sublingual and intradermal application of a vaccine, drug product is not yet on the market.

CTA control as intradermal and sublingual application

CTA mucosal adjuvans will be administered intradermally and sublingually

Group Type: EXPERIMENTAL

CTA control

Intervention Type: BIOLOGICAL

Sublingual and intradernal application of a mucosal adjuvance, drug product is not yet on the market.

Interventions

CTA control

Sublingual and intradernal application of a mucosal adjuvance, drug product is not yet on the market.

Intervention Type: BIOLOGICAL

IMX101 vaccine

Sublingual and intradermal application of a vaccine, drug product is not yet on the market.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• H. pylori-infected subjects: Confirmed H. pylori infection by urea breath test and serology.

H. pylori-negative subjects: Presenting no H. pylori infection by urea breath test and serology.

• Men and women aged ≥18 years and ≤ 50 years.
• Female subjects must either be of non-childbearing potential or use highly effective methods of contraception for at least 1 month prior to Screening and 1 month after end of study participation (see section pregnancy and contraceptives).
• Women with a negative serum test at Screening (V2) and women of childbearing potential additionally with a negative urine pregnancy test at each visit (except V1 and FU V10/V12).
• Have given written informed consent prior to admission to the study in accordance with ICH-GCP and local legislation.
• Ability to comply with the requirements of the study protocol.

Exclusion Criteria

• History of successful treatment for H. pylori infection.
• Regular use (once a week or more) of diclofenac, other non-steroidal anti-inflammatory drugs (NSAIDs), e.g. acetylsalicylic acid (Aspirin®), or proton pump inhibitor (PPI). Additionally, PPI is used within 2 weeks prior to V1 and V11.
• Use of anticoagulants (i.e. heparin, coumarin derivatives, e.g. Marcumar®).
• Use of antibiotics employed in H. pylori therapy within the month prior to study entry (V1) as well as 1 month prior to each endoscopy (V3 and V9/V11).
• Recent or current (within the last 6 months) systemic corticosteroid use including inhaled corticosteroids. Topical corticosteroid medication is allowed.
• Current or previous gastric ulcer diseases or preneoplastic changes in the stomach mucosa according to medical records or endoscopy findings confirmed by histological assessment at Baseline (V3).
• Current or previous medically significant gastroduodenal disease.
• Preceding cholera immunisation or disease.
• Uncontrolled hypertension or orthostatic hypotension.
• Body mass index (BMI) ≤ 18 or ≥ 30.
• Poorly-controlled type I or type II diabetes mellitus (glycosylated haemoglobin [HbA1c] ≥ 7.5% within the last 6 weeks) and subjects requiring insulin treatment.
• History, evidence or suspicion of tumour burden.
• Epilepsy or seizure disorder.
• Bleeding diathesis.
• Positive viral serology screening result for hepatitis B surface antigen (HBS Ag), antibodies to hepatitis C virus (HCV Ab), or human immunodeficiency virus (HIV) type 1 and 2.
• Known significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalisation.
• A history of active alcohol abuse or drug addiction.
• Administration of a live vaccine within 90 days prior to the first study immunisation (V4) and throughout the study.
• Receipt of blood, blood products or plasma derivatives 30 days prior to study entry (V1).
• Pregnancy or lactation.
• Participation in a clinical study within 30 days prior to admission to the study if investigational or marketed drug were employed. Any disease or condition which in the Investigator's opinion would exclude the subject from the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

ImevaX

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sandra Zivotic

Role: PRINCIPAL_INVESTIGATOR

CTC-NORTH

Locations

ClinicalTrial Site

Hamburg, , Germany

Clinical Trial Site

Munich, , Germany

Countries

Germany

Other Identifiers

2015-004761-82

Identifier Type: -

Identifier Source: org_study_id